Option Care Health vs Laboratory Corporation of America: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Option Care Health Inc (OPCH)

Q3 202614 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 202614 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest14 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Laboratory Corporation of America Holdings (LH)

Q3 202622 Jun – 22 Sep 2026

▲2▼1

Labcorp launches new tests, raises guidance, but Medicare fee cut proposal weighs

New product launches and Medicare coverage Labcorp launched ColoSense, the first FDA-approved at-home RNA colorectal cancer test, gained Medicare coverage for NASHnext, and introduced the first FDA-cleared Alzheimer's blood test. These expand its testing menu and open new revenue streams.
These launches are new in Q3 and show innovation driving growth.
Strong financial performance and raised guidance Labcorp beat Q2 estimates, raised its 2026 guidance, completed a large buyback, and set long-term revenue growth targets of 5%–8%. This signals confidence in its business and returns cash to shareholders.
These are new financial updates that positively influenced investor sentiment.
Proposed Medicare lab fee cuts CMS proposed cutting Medicare lab fees by up to 15% starting January 2027, citing overpayment versus private insurers. This sharply pressured Labcorp and Quest shares, raising concerns about future margins and revenue.
This is a new regulatory threat that negatively impacted the stock.
Reaffirmed outlook despite reimbursement pressure Labcorp reaffirmed its 2026–2029 outlook, saying it already assumed reimbursement pressure. However, the stock still fell about 3% in Q3, reflecting investor caution over potential margin and revenue risks.
This shows the counterweight: management confidence versus market skepticism.

September 202628 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

Latest28 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

July 202622 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.

22 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.